ArticleBrain pathology (Zurich, Switzerland)2010
Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas.
Article in Brain pathology (Zurich, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Prognostic utility and characteristics of MIB-1 labeling index as a proliferative activity marker in childhood low-grade glioma: a retrospective observational study.Journal of cancer research and clinical oncology · 2024Observational
- Clinical Characteristics and Long-term Outcomes of Spinal Pilocytic Astrocytomas: A Multicenter Retrospective Study by the Neurospinal Society of Japan.Neurospine · 2023Article
- Primary spinal pilocytic astrocytoma: clinical study with long-term follow-up in 16 patients and a literature review.Neurosurgical review · 2020Review
- The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.Neuro-oncology · 2019Review
- Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features.BMC cancer · 2015Article
- Pediatric cerebellar astrocytoma: a review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015Review
- BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors.Journal of neuro-oncology · 2013Article
- Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.Journal of neuropathology and experimental neurology · 2013Article
- Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.Neuro-oncology · 2012Article
- Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.Brain pathology (Zurich, Switzerland) · 2011Article
- Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.Neuro-oncology · 2011Article
- Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.Acta neuropathologica · 2010Article
- P53 and Ki-67 Expression in Primary Pediatric Brain Tumors: Does it Correlate with Presentation, Histological Grade, and Outcome?Asian journal of neurosurgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Pilocytic astrocytoma (PA) is the most common glioma in the pediatric population. PAs can exhibit variable behavior that does not always correlate with location, yet at present there is no way to predict which tumors will be more aggressive. To address this problem, an institutional cohort of 147 PAs (118 with outcome data) from both cerebellar and noncerebellar locations (spine, diencephalon, midbrain, brainstem and cortex) was utilized. Parameters included quantification of characteristic morphologic variables as well as genes previously shown to be of relevance in high-grade gliomas, including MIB-1, p53 and MGMT. In this cohort, the classic biphasic appearance was most common in cerebellar tumors, whereas noncerebellar tumors were predominantly microcystic. Associations with outcome suggest that the presence of degenerative atypia may be a favorable factor in PAs. Oligodendroglial morphology and the absence of leptomeningeal invasion are adverse histologic factors, but only in cerebellar tumors. Conversely, MIB-1 proliferation index and p53 and MGMT expression do not correlate with outcome. Morphologic biomarkers thus do exist for PAs, but the utility of each biomarker varies according to location. These results suggest that PAs differ fundamentally according to location; therefore, biological behavior may not simply depend on extent of resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.